Fursultiamine

Get a Price/Quote

Fursultiamine Specification

Efficacy
Promotes vitamin B1 activity, supports neurological health, and aids in the treatment of vitamin B1 deficiency.

Shelf Life
2 years

Strength
50 mg/tab, 100 mg/tab

Flavor
Odorless, tasteless

Best Before
2 years from manufacturing date

Effect
Increases thiamine blood levels and absorption, enhances nerve function

Origin
Japan

Medicine Type
Allopathic

Purity
99%

Chemical Composition
Fursultiamine hydrochloride, C17H26N4O3S2.HCl

Ingredients
Fursultiamine

Sub Ingredients
Thiamine derivative

Function
Vitamin supplement, neurological health improvement

Dosage Guidelines
Take orally with water, after meals

Dosage Form
Tablet

Storage Instructions
Store in a cool, dry place, protected from light and moisture

Packaging Size
30, 60, or 100 tablets per bottle or blister pack

Packaging Type
Bottle, Blister Pack

About Fursultiamine

Name: Fursultiamine
Synonyms:N-(4-Amino-2-methylpyrimidin-5-ylmethyl)-N-[4-hydroxy-1-methyl- 2-(tetrahydrofurfuryldithio)but-1-enyl]formamide
Molecular Formula:C17H26N4O3S2
Molecular Weight:398.55
CAS Registry Number:804-30-8
EINECS: 212-357-1

Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis
Object and design: The therapeutic effect of glucosamine hydrochloride (GH) and chondroitin sulfate (CS) in combination with fursultiamine, a vitamin B 1 derivative, on the development of cartilage lesions was investigated in an animal model of osteoarthritis (OA). Methods: The OA model was created by partial medial meniscectomy of the right knee joint (day 0). The rabbits were placed into three experimental groups: operated (OA) rabbits that received placebo treatment, OA rabbits that received GH (1000 mg/kg) + CS (800 mg/kg), and OA rabbits that received GH + CS + fursultiamine (100 mg/kg). Each treatment was initiated on day 3 and continued for 8 weeks. Macroscopic and histologic analyses were performed on the cartilage. The level of MMP-1 in OA cartilage chondrocytes was evaluated by immunohistochemistry. Results: Only the group receiving combined treatment with GH + CS + fursultiamine showed a significant reduction in the severity of macroscopic and histologic lesions on tibial plateau, which is the weight bearing cartilage surface of the tibia, compared with placebo-treated OA rabbits. This treatment group also revealed a small, but significant, decrease in the body weight gain of the rabbits. In cartilage from placebo-treated OA rabbits, a significantly higher percentage of chondrocytes in superficial layer stained positive for MMP-1 compared with unoperated control. Rabbits treated with the GH + CS + fursultiamine revealed a significant reduction in the level of MMP-1. Conclusion: These results suggest that the chondroprotective effect of GH + CS is enhanced by the addition of fursultiamine in experimental OA. This effect was associated with a reduction in the level of MMP-1, which are known to play an important role in the pathophysiology of OA lesions

Tell us about your requirement